NEW YORK, Dec 21 (Reuters) - Teva Pharmaceutical Industries Ltd said on Tuesday it has reached a deal with Japanese drugmaker Takeda Pharmaceutical Co that settles their patent infringement litigation over Takeda's widely used diabetes drug Actos.
Under the settlement, Takeda has granted Teva a license to market an authorized generic version of Actos in the United States beginning on Aug 17, 2012, or earlier under certain circumstances, Teva said.
The settlement also allows Israel-based Teva a license to market an authorized generic version of Takeda's Actosplus met, which combines Actos with two other common diabetes medicines, in the United States beginning on Dec 14, 2012.
The two brand products had combined annual sales of about $4 billion in the United States, according to sales data compiled by IMS Health.
Takeda in April announced settlements of lawsuits against six other companies seeking to market cheap generic versions of Actos and Actosplus met.
As part of those settlements, the Japanese drugmaker granted licenses to also begin selling generic Actos on Aug 17, 2012 to Mylan Inc, Watson Pharmaceuticals Inc and India's Ranbaxy Laboratories Ltd.
Teva is the world's largest maker of generic medicines.
(Reporting by Bill Berkrot; editing by Carol Bishopric) Keywords: TEVA TAKEDA/SETTLEMENT (bill.berkrot@thomsonreuters.com; +1 646 223-6030; Reuters Messaging: bill.berkrot.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Under the settlement, Takeda has granted Teva a license to market an authorized generic version of Actos in the United States beginning on Aug 17, 2012, or earlier under certain circumstances, Teva said.
The settlement also allows Israel-based Teva a license to market an authorized generic version of Takeda's Actosplus met, which combines Actos with two other common diabetes medicines, in the United States beginning on Dec 14, 2012.
The two brand products had combined annual sales of about $4 billion in the United States, according to sales data compiled by IMS Health.
Takeda in April announced settlements of lawsuits against six other companies seeking to market cheap generic versions of Actos and Actosplus met.
As part of those settlements, the Japanese drugmaker granted licenses to also begin selling generic Actos on Aug 17, 2012 to Mylan Inc, Watson Pharmaceuticals Inc and India's Ranbaxy Laboratories Ltd.
Teva is the world's largest maker of generic medicines.
(Reporting by Bill Berkrot; editing by Carol Bishopric) Keywords: TEVA TAKEDA/SETTLEMENT (bill.berkrot@thomsonreuters.com; +1 646 223-6030; Reuters Messaging: bill.berkrot.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.